- Discuss the differences in dosing regimens and outcomes for anti-VEGF treatments for DME.
- Describe how anti-VEGF is being used in clinical practice, as compared to dosing regimens of large phase 3 trials.
- Identify new developments and recommendations for the use of vitamin supplementation for patients with AMD as it relates to genetic polymorphisms.
- Summarize current trials and the anticipated trial results relating to retinal diseases expected in 2015.
Retina 2014 – Highlights and Hallmarks
The live program has concluded.
If you attended, please click on the "Take Post-Test" button to claim your credit. If you did not attend, please stay tuned for the archived version, which will be available soon for on-demand viewing.
Details
Learning Objectives
LEARNING OBJECTIVES: At the end of this activity, participants will be able to: Participation Method
METHOD OF INSTRUCTION: After reviewing the material in its entirety, please complete the self-assessment test, which consists of a series of multiple-choice questions, and the course evaluation. To answer these questions online and receive real-time results, please visit www.dulaneyfoundation.org and click “Online Courses.” Upon completing the activity and achieving a passing score of higher than 70% on the self-assessment test, you may print out a CME credit letter awarding 1.0 AMA PRA Category 1 Credit.™ The estimated time to complete this activity is 1.0 hour. Faculty and Disclosures
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.Disclaimer
DISCLOSURE POLICY: In accordance with the disclosure policies of the Dulaney Foundation and to conform with ACCME and US Food and Drug Administration guidelines, anyone in a position to affect the content of a CME activity is required to disclose to the activity participants (1) the existence of any financial interest or other relationships with the manufacturers of any commercial products/devices or providers of commercial services and (2) identification of a commercial product/device that is unlabeled for use or an investigational use of a product/ device not yet approved. DISCLAIMER: The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of The Dulaney Foundation, Avlis International, Inc., or Regeneron Pharmaceuticals. System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Expiration Date:
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Yewlin E. Chee, MD
Camila Ventura MD, PhD
Edward Wood, MD
Tony Capone Jr, MD
Katherine E. Talcott, MD
Nassim Abreu, MD
- CME/CE In-Person & Virtual Event
Treating Outside the Box: New Pathways to Retinal Vascular Stability
July 17, 2026
Montreal Katherine E. Talcott, MD
Christina Y. Weng, MD, MBA, FASRS
Roger A. Goldberg, MD, MBA
